You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 5,591,639

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,591,639

Title:	Recombinant DNA expression vectors
Abstract:	The invention provides expression vectors containing the promoter, enhancer and substantially complete 5\'-untranslated region including the first intron of the major immediate early gene of human cytomegalovirus. Further vectors including the hCMV-MIE DNA linked directly to the coding sequence of a heterologous gene are described, Host cells transfected with the vectors and a process for producing heterologous polypeptides using the vectors and the use of the hCMV-MIE DNA for expression of a heterologous gene are also included within the invention.
Inventor(s):	Bebbington; Christopher R. (Windsor, GB)
Assignee:	Celltech Ltd (Berkshire, GB)
Application Number:	08/300,063
Patent Claims:	1. Plasmids pCMGS, pEE6.hCMV and pHT.1. 2. A recombinant expression vector comprising the promoter, enhancer and complete 5' untranslated region including the first intron of the hCMV-MIE gene operably linked to a heterologous coding sequence. 3. The recombinant expression vector according to claim 2 further comprising a restriction site to facilitate insertion of the heterologous coding sequence. 4. The recombinant expression vector according to claim 2 wherein the promoter, enhancer and complete 5' untranslated region including the first intron of the hCMV-MIE gene are linked directly to the heterologous coding sequence. 5. The recombinant expression vector according to claim 2 wherein the vector further includes the translation initiation signal of the hCMV MIE gene translational initiation signal. 6. The recombinant expression vector according to claim 5 wherein the translational initiation signal includes the sequence 5'-GTCACCGTCCTTGACACCATG-3'. 7. The recombinant expression vector according to claim 5 wherein the translational initiation signal includes the sequence 5'-CCATGG-3'.

Details for Patent 5,591,639

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2014-01-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2014-01-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2014-01-07
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.